Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle
暂无分享,去创建一个
Magdalena Nauerth | V. Ortiz-Maldonado | Julio Delgado | Pere Barba | Linda Warmuth | P. Staber | Benno Lickefett | Lulu Chu | Matteo Doglio | David Henderson | Michael Hudecek | Andreas Kremer | Janet Markman | Helene Negre | Carmen Sanges | Rebecca Tanzi | Dirk H. Busch | Jürgen H. E. Kuball | Maik Luu | Ulrich Jäger
[1] B. Sahaf,et al. Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma , 2023, Blood cancer journal.
[2] N. Ajami,et al. Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring. , 2023, Cancer cell.
[3] S. Ong,et al. Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma , 2023, American journal of hematology.
[4] E. Giné,et al. P1394: RITUXIMAB BASED LYMPHODEPLETION MAY INCREASE ENGRAFTMENT AND EFFICACY OF SECOND INFUSIONS OF CART19 CELLS IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. , 2023, HemaSphere.
[5] M. Juan,et al. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study. , 2023, The Lancet. Oncology.
[6] R. Houot,et al. Immune Effector Cell-Associated Hematotoxicity (ICAHT): EHA/EBMT Consensus Grading and Best Practice Recommendations. , 2023, Blood.
[7] J. Kochenderfer,et al. Long-term outcomes following CAR T cell therapy: what we know so far , 2023, Nature Reviews Clinical Oncology.
[8] Stacy L. Gelhaus,et al. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment , 2023, Cell.
[9] N. Hijiya,et al. Clofarabine for Lymphodepletion Before CAR-T-Cell Infusion: A Brief Case Report , 2023, Journal of pediatric hematology/oncology.
[10] B. Baradaran,et al. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies , 2023, Frontiers in Immunology.
[11] E. Elinav,et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy , 2023, Nature Medicine.
[12] Alessandra M. Sullivan,et al. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering , 2023, Journal for ImmunoTherapy of Cancer.
[13] M. Ayas,et al. Clofarabine in Pediatric Acute Relapsed or Refractory Leukemia: Where Do We Stand on the Bridge to Hematopoietic Stem Cell Transplantation? , 2023, Journal of hematology.
[14] M. Liedtke,et al. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results , 2023, Nature Medicine.
[15] P. Riedell,et al. Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium , 2022, Blood.
[16] Y. Taur,et al. Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy , 2022, Nature Medicine.
[17] Matthew J. Frigault,et al. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. , 2022, The Lancet. Haematology.
[18] H. Mollenkopf,et al. Selected commensals educate the intestinal vascular and immune system for immunocompetence , 2022, Microbiome.
[19] R. Houot,et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma , 2022, Nature Medicine.
[20] F. Locke,et al. Outcomes of CD19 targeted CAR T-cell Therapy for Patients with Reduced Renal Function Including Dialysis. , 2022, Transplantation and cellular therapy.
[21] U. Jäger,et al. Bendamustine is Safe and Effective for Lymphodepletion Before Tisagenlecleucel in Patients with Refractory or Relapsed Large B-Cell Lymphomas. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] J. Byrd,et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia , 2022, Blood advances.
[23] C. Ramos,et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion , 2022, Nature Reviews Clinical Oncology.
[24] B. Baradaran,et al. A Systematic Review on PD-1 Blockade and PD-1 Gene-Editing of CAR-T Cells for Glioma Therapy: From Deciphering to Personalized Medicine , 2022, Frontiers in Immunology.
[25] D. Weissman,et al. CAR T cells produced in vivo to treat cardiac injury , 2022, Science.
[26] R. de Waal Malefyt,et al. An orthogonal IL-2 and IL-2Rβ system drives persistence and activation of CAR T cells and clearance of bulky lymphoma , 2021, Science Translational Medicine.
[27] M. Kersten,et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial , 2021, Nature Medicine.
[28] G. Salles,et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. , 2021, The Lancet. Oncology.
[29] Snehit Prabhu,et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy , 2021, Blood advances.
[30] A. Huitema,et al. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia , 2021, Blood advances.
[31] U. Jaeger,et al. Bendamustine Is a Safe and Effective Regimen for Lymphodepletion before Tisagenlecleucel in Patients with Large B-Cell Lymphomas , 2021, Blood.
[32] P. Riedell,et al. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL , 2021, Blood.
[33] M. Hallek,et al. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures , 2021, American journal of hematology.
[34] M. Abbasian,et al. Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] M. Perales,et al. Modified-EASIX predicts severe cytokine release syndrome and neurotoxicity after Chimeric Antigen Receptor (CAR) T cells. , 2021, Blood advances.
[36] M. Kersten,et al. Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA‐1, and TRANSCEND trials , 2021, American journal of hematology.
[37] T. Gress,et al. Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer , 2021, Nature Communications.
[38] E. Hoster,et al. CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma. , 2021, Blood.
[39] S. Jagannath,et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study , 2021, The Lancet.
[40] R. Houot,et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study , 2021, The Lancet.
[41] R. Simpson,et al. Immunomodulatory Effects of Bendamustine in Hematopoietic Cell Transplantation , 2021, Cancers.
[42] S. Steinberg,et al. Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] H. Goldschmidt,et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. , 2021, The New England journal of medicine.
[44] J. Maher,et al. Crosstown Traffic: Lymphodepleting Chemotherapy Drives CAR T Cells. , 2020, Cancer cell.
[45] A. M. Houghton,et al. Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. , 2020, Cancer cell.
[46] E. Giné,et al. CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.
[47] Michael L. Wang,et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study , 2020, The Lancet.
[48] J. Serody,et al. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] H. Abken,et al. TRUCKS, the fourth‐generation CAR T cells: Current developments and clinical translation , 2020, ADVANCES IN CELL AND GENE THERAPY.
[50] Michael L. Wang,et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. , 2020, The New England journal of medicine.
[51] A. Huitema,et al. A semi‐mechanistic model based on glutathione depletion to describe intra‐individual reduction in busulfan clearance , 2020, British journal of clinical pharmacology.
[52] Oliver J. Klein,et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors , 2020, Science.
[53] David A. Williams,et al. Toxicity and Response following CD19-specific CAR T cells in pediatric/young adult relapsed/refractory B-ALL. , 2019, Blood.
[54] S. Grupp,et al. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] A. d’Arminio Monforte,et al. Disseminated cytomegalovirus disease after bendamustine: a case report and analysis of circulating B- and T-cell subsets , 2019, BMC Infectious Diseases.
[56] A. Huitema,et al. Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes. , 2019, Blood advances.
[57] Y. Shimizu. Faculty Opinions recommendation of An effective mouse model for adoptive cancer immunotherapy targeting neoantigens. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[58] N. Restifo,et al. An effective mouse model for adoptive cancer immunotherapy targeting neoantigens. , 2019, JCI insight.
[59] D. Maloney,et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. , 2019, Blood.
[60] S. Neelapu. CAR-T efficacy: is conditioning the key? , 2019, Blood.
[61] D. Maloney,et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. , 2019, Blood.
[62] Boris Lamp,et al. The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes , 2019, Nature Communications.
[63] G. Salles,et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma , 2019, The New England journal of medicine.
[64] I. Flinn,et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. , 2019, The Lancet. Oncology.
[65] M. Sadelain,et al. Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.
[66] A. Huitema,et al. Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation , 2018, Clinical Pharmacokinetics.
[67] S. Mehrotra,et al. Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells. , 2018, Cancer research.
[68] M. Spitzer,et al. Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System , 2018, Cell reports.
[69] Hans Bitter,et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia , 2018, Nature Medicine.
[70] C. June,et al. CAR T cell immunotherapy for human cancer , 2018, Science.
[71] K. Tamada,et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor , 2018, Nature Biotechnology.
[72] K. Davis,et al. Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.
[73] Mithat Gonen,et al. Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.
[74] D. Gilham,et al. CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity , 2017, Molecular therapy oncolytics.
[75] R. Levy,et al. Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.
[76] Daniel Li,et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. , 2017, Blood.
[77] R. Kruse,et al. Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. , 2017, Cancer discovery.
[78] J. Byrd,et al. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] S. Riddell,et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. , 2017, Blood.
[80] Michel Sadelain,et al. Therapeutic T cell engineering , 2017, Nature.
[81] C. van Kesteren,et al. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis. , 2017, The Lancet. Haematology.
[82] S. Heimfeld,et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells , 2016, Science Translational Medicine.
[83] M. Sabatino,et al. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. , 2016, Blood.
[84] Daniel Li,et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. , 2016, The Journal of clinical investigation.
[85] E. Kimby,et al. Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update , 2015, Leukemia & lymphoma.
[86] H. Döhner,et al. Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG) , 2015, Haematologica.
[87] D. Maloney,et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo , 2015, Leukemia.
[88] David L. Porter,et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.
[89] L. Specht,et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. , 2015, International journal of radiation oncology, biology, physics.
[90] S. Steinberg,et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.
[91] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.
[92] B. Sandmaier,et al. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. , 2014, Blood.
[93] H. Eich,et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). , 2014, International journal of radiation oncology, biology, physics.
[94] J. Burke,et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. , 2014, Blood.
[95] T. Cooper,et al. Whole-Body Irradiation Increases the Magnitude and Persistence of Adoptively Transferred T Cells Associated with Tumor Regression in a Mouse Model of Prostate Cancer , 2014, Cancer Immunology Research.
[96] A. Ng,et al. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. , 2014, International journal of radiation oncology, biology, physics.
[97] Qing He,et al. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.
[98] Michel Sadelain,et al. CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia , 2013, PloS one.
[99] C. Guillemette,et al. Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. , 2013, Blood.
[100] Jinjuan Wang,et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. , 2012, Blood.
[101] Michel Sadelain,et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.
[102] H. Döhner,et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[103] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.
[104] David L. Porter,et al. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.
[105] W. Wilson,et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.
[106] S. Rosenberg,et al. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. , 2010, Blood.
[107] R. Greil,et al. Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia , 2010, Cancer Immunology, Immunotherapy.
[108] M. Kalos,et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[109] M. Sadelain,et al. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[110] M. Atkins,et al. Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[111] S. Dovedi,et al. Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T Cells , 2010, The Journal of Immunology.
[112] T. Pavlík,et al. Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients. , 2009, Experimental hematology.
[113] T. Tani,et al. Pre-treatment with cyclophosphamide or OX40 (CD134) costimulation targeting regulatory T cell function enhances the anti-tumor immune effect of adoptively transferred CD8+ T cells from wild-type mice. , 2009, Molecular medicine reports.
[114] C. Yee,et al. Fludarabine Modulates Immune Response and Extends In Vivo Survival of Adoptively Transferred CD8 T Cells in Patients with Metastatic Melanoma , 2009, PloS one.
[115] Brian R. Phillips,et al. A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients , 2009, Cancer Chemotherapy and Pharmacology.
[116] S. Rosenberg,et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[117] Jinjuan Wang,et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. , 2008, Blood.
[118] J. Mulé,et al. Nonmyeloablative Chemotherapy Followed by T-cell Adoptive Transfer and Dendritic Cell-based Vaccination Results in Rejection of Established Melanoma , 2008, Journal of immunotherapy.
[119] Christian Stemberger,et al. A single naive CD8+ T cell precursor can develop into diverse effector and memory subsets. , 2007, Immunity.
[120] V. Maguer-Satta,et al. In Vitro Toxicity of Fludarabine on Normal Bone Marrow (BM) Progenitors Suggests Its Involvement in the Impairment of Hematopoietic Progenitor (HP) Mobilization. , 2007 .
[121] S. Rosenberg,et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. , 2007, The Journal of clinical investigation.
[122] S. Rosenberg,et al. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. , 2007, The Journal of clinical investigation.
[123] J. Delabie,et al. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma , 2007, Leukemia & lymphoma.
[124] S. Rosenberg,et al. Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go? , 2006, Nature Clinical Practice Oncology.
[125] C. Klebanoff,et al. Interleukin-2-Dependent Mechanisms of Tolerance and Immunity In Vivo1 , 2006, The Journal of Immunology.
[126] A. Zelenetz,et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[127] B. D. de Pauw,et al. Microbiologic consequences of new approaches to managing hematologic malignancies. , 2005, Reviews in clinical and experimental hematology.
[128] N. Schmitz,et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.
[129] G. Plautz,et al. Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells. , 2005, Cancer research.
[130] S. Rosenberg,et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells , 2005, The Journal of experimental medicine.
[131] Xiaojing Ma,et al. Interleukin-12: an update on its immunological activities, signaling and regulation of gene expression. , 2005, Current immunology reviews.
[132] N. Restifo,et al. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. , 2005, Current opinion in immunology.
[133] J. Schlom,et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. , 2005, Blood.
[134] S. Rosenberg,et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[135] S. Rosenberg,et al. CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells , 2005, The Journal of Immunology.
[136] C. Klebanoff,et al. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. , 2005, Trends in immunology.
[137] George Coukos,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.
[138] B. Chauffert,et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative , 2004, European journal of immunology.
[139] M. Raffeld,et al. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.
[140] C. June,et al. Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation1 , 2002, The Journal of Immunology.
[141] N. Hayashi,et al. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. , 2001, Cancer research.
[142] Jianzhu Chen,et al. Homeostasis-Stimulated Proliferation Drives Naive T Cells to Differentiate Directly into Memory T Cells , 2000, The Journal of experimental medicine.
[143] L. Bogatzki,et al. Naive T Cells Transiently Acquire a Memory-like Phenotype during Homeostasis-Driven Proliferation , 2000, The Journal of experimental medicine.
[144] R. Ahmed,et al. Cutting Edge: Naive T Cells Masquerading as Memory Cells , 2000, The Journal of Immunology.
[145] J. Shimizu,et al. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.
[146] J. Sprent,et al. The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. , 1999, Immunity.
[147] K. Brduscha-Riem,et al. Naïve cytotoxic T lymphocytes spontaneously acquire effector function in lymphocytopenic recipients: A pitfall for T cell memory studies? , 1999, European journal of immunology.
[148] E. Proietti,et al. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. , 1998, The Journal of clinical investigation.
[149] Julie C. Adkins,et al. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. , 1997, Drugs.
[150] B. Rocha,et al. Peripheral selection of the T cell repertoire. , 1991, Science.
[151] Z. Eshhar,et al. Chimeric T cell receptor which incorporates the anti-tumour specificity of a monoclonal antibody with the cytolytic activity of T cells: a model system for immunotherapeutical approach. , 1990, The British journal of cancer. Supplement.
[152] Z. Eshhar,et al. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[153] M. Drayson,et al. The stable and permanent expansion of functional T lymphocytes in athymic nude rats after a single injection of mature T cells. , 1987, Journal of immunology.
[154] S. Rosenberg,et al. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.
[155] R. North. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells , 1982, The Journal of experimental medicine.
[156] P. Greenberg,et al. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. , 1980, Journal of immunology.
[157] A. Einstein,et al. Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells. , 1975, Journal of immunology.
[158] M. Perales,et al. Modi fi ed EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells , 2021 .
[159] J. Markmann,et al. Homeostatic proliferation is a barrier to transplantation tolerance , 2004, Nature Medicine.
[160] M. Hallek,et al. Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia. , 2004, The hematology journal : the official journal of the European Haematology Association.
[161] A. Sparreboom,et al. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[162] Pierre Morel,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.